Overview

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on efficacy and safety of pazopanib as a first-line therapy in practice usual for the clinical treatment of metastatic Renal Carcinoma.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Spanish Oncology Genito-Urinary Group
Criteria
Inclusion Criteria:

- Patients ≥ 18.

- Metastatic renal cell cancer of any histology.

- Patients treated with pazopanib for metastatic cell renal cancer outside the context
of clinical trials (clinical practice) in Spanish centers from 1 April 2011 until 30
June 2014. shall be included all patients who received pazopanib as first-line
treatment in each participating center, whether had experienced treatment failure with
pazopanib or were still in first-line treatment. The inclusion of patients who are
also allowed received cytokine as first-line treatment followed by pazopanib as well
as patients who received sunitinib as first-line treatment and have changed pazopanib
for toxicity or intolerance, provided they have not received more a cycle of
sunitinib.

- Centers that agree to participate must commit to: · Include all patients meeting the
inclusion criteria to reduce by possible selection bias. Because it supplies only
pazopanib Hospital pharmacy service (not outside hospitals), the identification of
patients will be performed at the hospital pharmacy records in each participating
center.

Exclusion Criteria:

- Patients who received pazopanib in clinical trials or treatment second line, with the
exceptions noted above.

- Patients with the diagnosis and / or treatment of malignancies of importance other
than Cell renal cancer.